|
1
|
Singh K, Mukherjee AB, De Vouge MW and
Mukherjee BB: Differential processing of osteopontin transcripts in
rat kidney- and osteoblast-derived cell lines. J Biol Chem.
267:23847–23851. 1992.PubMed/NCBI
|
|
2
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Simpson S, Dunning MD, de Brot S,
Grau-Roma L, Mongan NP and Rutland CS: Comparative review of human
and canine osteosarcoma: Morphology, epidemiology, prognosis,
treatment and genetics. Acta Vet Scand. 59:712017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Longhi A, Errani C, De Paolis M, Mercuri M
and Bacci G: Primary bone osteosarcoma in the pediatric age: State
of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Selmic LE, Burton JH, Thamm DH, Withrow SJ
and Lana SE: Comparison of carboplatin and doxorubicin-based
chemotherapy protocols in 470 dogs after amputation for treatment
of appendicular osteosarcoma. J Veterin Internal Med. 28:554–563.
2014. View Article : Google Scholar
|
|
6
|
Reddy KI, Wafa H, Gaston CL, Grimer RJ,
Abudu AT, Jeys LM, Carter SR and Tillman RM: Does amputation offer
any survival benefit over limb salvage in osteosarcoma patients
with poor chemonecrosis and close margins? Bone Joint J.
97-B:115–120. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ferrari S and Serra M: An update on
chemotherapy for osteosarcoma. Exp Opin Pharmacother. 16:2727–2736.
2015. View Article : Google Scholar
|
|
8
|
Wang WG, Wan C and Liao GJ: The efficacy
of high-dose versus moderate-dose chemotherapy in treating
osteosarcoma: A systematic review and meta-analysis. In J Clin Exp
Med. 8:15967–15974. 2015.
|
|
9
|
Zhang FY, Tang W, Zhang ZZ, Huang JC,
Zhang SX and Zhao XC: Systematic review of high-dose and
standard-dose chemotherapies in the treatment of primary
well-differentiated osteosarcoma. Tum Biol. 35:10419–10427. 2014.
View Article : Google Scholar
|
|
10
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: state of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang N, Song WX, Luo J, Haydon RC and He
TC: Osteosarcoma development and stem cell differentiation. Clin
Orthop Rel Res. 466:2114–2130. 2008. View Article : Google Scholar
|
|
12
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Allen JI and Moore MN: Environmental
prognostics: Is the current use of biomarkers appropriate for
environmental risk evaluation? Mar Environ Res. 58:227–232. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chaturvedi S and McCrae KR: Clinical risk
assessment in the antiphospholipid syndrome: Current landscape and
emerging biomarkers. Curr Rheumatol Rep. 19:432017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moutzouri E, Tsimihodimos V and Tselepis
AD: Inflammatory biomarkers and cardiovascular risk assessment.
Current knowledge and future perspectives. Curr Pharm Design.
19:3827–3840. 2013. View Article : Google Scholar
|
|
16
|
Dijkstra S, Mulders PF and Schalken JA:
Clinical use of novel urine and blood based prostate cancer
biomarkers: A review. Clin Biochem. 47:889–896. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kai K, Dittmar RL and Sen S: Secretory
microRNAs as biomarkers of cancer. Semin Cell Develop Biol.
2017.
|
|
18
|
Li S, Liu X, Liu T, Meng X, Yin X, Fang C,
Huang D, Cao Y, Weng H, Zeng X and Wang X: Identification of
Biomarkers Correlated with the TNM Staging and Overall Survival of
Patients with Bladder Cancer. Front Physiol. 8:9472017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Van Loon K and Venook AP: Biomarkers in
colon cancer: The chasm between expectations and reality. Oncology
(Williston Park). 27:758–763. 2013.PubMed/NCBI
|
|
20
|
Senger DR, Wirth DF and Hynes RO:
Transformed mammalian cells secrete specific proteins and
phosphoproteins. Cell. 16:885–893. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Franzen A and Heinegard D: Isolation and
characterization of two sialoproteins present only in bone
calcified matrix. Biochem J. 232:715–724. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rangaswami H, Bulbule A and Kundu GC:
Osteopontin: Role in cell signaling and cancer progression. Trends
Cell Biol. 16:79–87. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kazanecki CC, Uzwiak DJ and Denhardt DT:
Control of osteopontin signaling and function by post-translational
phosphorylation and protein folding. J Cell Biochem. 102:912–924.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tuck AB, Chambers AF and Allan AL:
Osteopontin overexpression in breast cancer: Knowledge gained and
possible implications for clinical management. J Cell Biochem.
102:859–868. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E,
Lee NP, Wu GH and Luk JM: Osteopontin as potential biomarker and
therapeutic target in gastric and liver cancers. World J
Gastroenterol. 18:3923–3930. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Denhardt DT and Guo X: Osteopontin: A
protein with diverse functions. FASEB J. 7:1475–1482. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
El-Tanani MK: Role of osteopontin in
cellular signaling and metastatic phenotype. Front Biosci.
13:4276–4284. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boldrini L, Donati V, Dell'Omodarme M,
Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M,
Basolo F and Fontanini G: Prognostic significance of osteopontin
expression in early-stage non-small-cell lung cancer. Brit J
Cancer. 93:453–457. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chambers AF, Wilson SM, Kerkvliet N,
O'Malley FP, Harris JF and Casson AG: Osteopontin expression in
lung cancer. Lung Cancer. 15:311–323. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun
W, Han N, Ma Y, Di X, Gao M, et al: Overexpression of osteopontin
is associated with more aggressive phenotypes in human non-small
cell lung cancer. Clin Cancer Res. 11:4646–4652. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mack PC, Redman MW, Chansky K, Williamson
SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ and
Gandara DR: SWOG Lower osteopontin plasma levels are associated
with superior outcomes in advanced non-small-cell lung cancer
patients receiving platinum-based chemotherapy: SWOG Study S0003. J
Clin Oncol. 26:4771–4776. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ostheimer C, Bache M, Guttler A, Reese T
and Vordermark D: Prognostic information of serial plasma
osteopontin measurement in radiotherapy of non-small-cell lung
cancer. BMC Cancer. 14:8582014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ostheimer C, Gunther S, Bache M,
Vordermark D and Multhoff G: Dynamics of heat shock protein 70
serum levels as a predictor of clinical response in non-small-cell
lung cancer and correlation with the hypoxia-related marker
osteopontin. Front Immunol. 8:13052017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ostheimer C, Schweyer F, Reese T, Bache M
and Vordermark D: The relationship between tumor volume changes and
serial plasma osteopontin detection during radical radiotherapy of
non-small-cell lung cancer. Oncology Lett. 12:3449–3456. 2016.
View Article : Google Scholar
|
|
35
|
Schneider S, Yochim J, Brabender J, Uchida
K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Hölscher AH
and Danenberg PV: Osteopontin but not osteonectin messenger RNA
expression is a prognostic marker in curatively resected non-small
cell lung cancer. Clin Cancer Res. 10:1588–1596. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shi L and Wang X: Role of osteopontin in
lung cancer evolution and heterogeneity. Sem Cell Develop Biol.
64:40–47. 2017. View Article : Google Scholar
|
|
37
|
Wang M, Han J, Marcar L, Black J, Liu Q,
Li X, Nagulapalli K, Sequist LV, Mak RH, Benes CH, et al: Radiation
Resistance in kras-mutated lung cancer is enabled by stem-like
Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res.
77:2018–2028. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Anborgh PH, Caria LB, Chambers AF, Tuck
AB, Stitt LW and Brackstone M: Role of plasma osteopontin as a
biomarker in locally advanced breast cancer. Am J Transl Res.
7:723–732. 2015.PubMed/NCBI
|
|
39
|
Das R, Mahabeleshwar GH and Kundu GC:
Osteopontin stimulates cell motility and nuclear factor
kappaB-mediated secretion of urokinase type plasminogen activator
through phosphatidylinositol 3-kinase/Akt signaling pathways in
breast cancer cells. J Biol Chem. 278:28593–28606. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gu M and Zheng X: Osteopontin and
vasculogenic mimicry formation are associated with response to
neoadjuvant chemotherapy in advanced breast cancer. OncoTargets
Ther. 10:4121–4127. 2017. View Article : Google Scholar
|
|
41
|
Psyrri A, Kalogeras KT, Wirtz RM,
Kouvatseas G, Karayannopoulou G, Goussia A, Zagouri F, Veltrup E,
Timotheadou E, Gogas H, et al: Association of osteopontin with
specific prognostic factors and survival in adjuvant breast cancer
trials of the hellenic cooperative oncology group. J Transl Med.
15:302017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tuck AB and Chambers AF: The role of
osteopontin in breast cancer: Clinical and experimental studies. J
Mamm Gland Biolo Neopl. 6:419–429. 2001. View Article : Google Scholar
|
|
43
|
Zduniak K, Agrawal A, Agrawal S, Hossain
MM, Ziolkowski P and Weber GF: Osteopontin splice variants are
differential predictors of breast cancer treatment responses. BMC
Cancer. 16:4412016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ding L and Zheng S: Expression and
clinical significance of osteopontin in colorectal cancer and liver
metastatic tissues. Zhonghua wai ke za zhi. 40:773–775. 2002.(In
Chinese). PubMed/NCBI
|
|
45
|
Ding L, Zheng S and Cao J: Expression of
osteopontin mRNA and its protein in colorectal cancer and liver
metastatic tissues. Zhonghua yi xue za zhi. 82:970–973. 2002.(In
Chinese). PubMed/NCBI
|
|
46
|
Gu X, Gao XS, Ma M, Qin S, Qi X, Li X, Sun
S, Yu H, Wang W and Zhou D: Prognostic significance of osteopontin
expression in gastric cancer: A meta-analysis. Oncotarget.
7:69666–69673. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Imano M, Okuno K, Itoh T, Satou T,
Ishimaru E, Yasuda T, Hida J, Imamoto H, Takeyama Y and Shiozaki H:
Osteopontin induced by macrophages contribute to metachronous liver
metastases in colorectal cancer. Am Surg. 77:1515–1520.
2011.PubMed/NCBI
|
|
48
|
Ito T, Hashimoto Y, Tanaka E, Kan T,
Tsunoda S, Sato F, Higashiyama M, Okumura T and Shimada Y: An
inducible short-hairpin RNA vector against osteopontin reduces
metastatic potential of human esophageal squamous cell carcinoma in
vitro and in vivo. Clin Cancer Res. 12:1308–1316. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kolb A, Kleeff J, Guweidhi A, Esposito I,
Giese NA, Adwan H, Giese T, Büchler MW, Berger MR and Friess H:
Osteopontin influences the invasiveness of pancreatic cancer cells
and is increased in neoplastic and inflammatory conditions. Canc
Biol Ther. 4:740–746. 2005. View Article : Google Scholar
|
|
50
|
Lazar M, Sullivan J, Chipitsyna G, Gong Q,
Ng CY, Salem AF, Aziz T, Witkiewicz A, Denhardt DT, Yeo CJ and
Arafat HA: Involvement of osteopontin in the matrix-degrading and
proangiogenic changes mediated by nicotine in pancreatic cancer
cells. J Gastroint Surgery. 14:1566–1577. 2010. View Article : Google Scholar
|
|
51
|
Li JJ, Li HY and Gu F: Diagnostic
significance of serum osteopontin level for pancreatic cancer: a
meta-analysis. Gen Test Mol Biomarkers. 18:580–586. 2014.
View Article : Google Scholar
|
|
52
|
Lin J, Myers AL, Wang Z, Nancarrow DJ,
Ferrer-Torres D, Handlogten A, Leverenz K, Bao J, Thomas DG, Wang
TD, et al: Osteopontin (OPN/SPP1) isoforms collectively enhance
tumor cell invasion and dissemination in esophageal adenocarcinoma.
Oncotarget. 6:22239–22257. 2015.PubMed/NCBI
|
|
53
|
Liu G, Fan X, Tang M, Chen R, Wang H, Jia
R, Zhou X, Jing W, Wang H, Yang Y, et al: Osteopontin induces
autophagy to promote chemo-resistance in human hepatocellular
carcinoma cells. Cancer Lett. 383:171–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Loosen SH, Roderburg C, Kauertz KL,
Pombeiro I, Leyh C, Benz F, Vucur M, Longerich T, Koch A,
Braunschweig T, et al: Elevated levels of circulating osteopontin
are associated with a poor survival after resection of
cholangiocarcinoma. J Hepatology. 67:749–757. 2017. View Article : Google Scholar
|
|
55
|
Ng L, Wan T, Chow A, Iyer D, Man J, Chen
G, Yau TC, Lo O, Foo CC, Poon JT, et al: Osteopontin overexpression
induced tumor progression and chemoresistance to oxaliplatin
through induction of stem-like properties in human colorectal
cancer. Stem Cells Int. 2015:2478922015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sulpice L, Rayar M, Desille M, Turlin B,
Fautrel A, Boucher E, Llamas-Gutierrez F, Meunier B, Boudjema K,
Clément B and Coulouarn C: Molecular profiling of stroma identifies
osteopontin as an independent predictor of poor prognosis in
intrahepatic cholangiocarcinoma. Hepatology. 58:1992–2000. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Terashi T, Aishima S, Taguchi K, Asayama
Y, Sugimachi K, Matsuura S, Shimada M, Maehara S, Maehara Y and
Tsuneyoshi M: Decreased expression of osteopontin is related to
tumor aggressiveness and clinical outcome of intrahepatic
cholangiocarcinoma. Liver Int. 24:38–45. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ue T, Yokozaki H, Kitadai Y, Yamamoto S,
Yasui W, Ishikawa T and Tahara E: Co-expression of osteopontin and
CD44v9 in gastric cancer. Inte J Cancer. 79:127–132. 1998.
View Article : Google Scholar
|
|
59
|
Weber CE, Erşahin ÇH, Kuo PC and Mi Z:
Pancreatic Cancer and Osteopontin: The Relationship Remains
Unclear. Pancreas. 45:e35–e36. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wu H, Zhang H, Hu LY, Zhang TY, Zheng YJ,
Shen F and Yang T: Is osteopontin a promising prognostic biomarker
for cholangiocarcinoma? J Hepatol. Sep 20–2017.(Epub ahead of
print).
|
|
61
|
Wu IC, Wu MT, Chou SH, Yang SF, Goan YG,
Lee JM, Chou YP, Bair MJ, Wang TE, Chen A, et al: Osteopontin
expression in squamous cell cancer of the esophagus. World J Surg.
32:1989–1995. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhang HZ, Liu JG, Wei YP, Wu C, Cao YK and
Wang M: Expressions of RhoC and osteopontin in esophageal squamous
carcinoma and association with the patients' prognosis. Nan Fang Yi
Ke Da Xue Xue Bao. 26:1612–1615. 2006.(in Chinese). PubMed/NCBI
|
|
63
|
Forootan SS, Foster CS, Aachi VR, Adamson
J, Smith PH, Lin K and Ke Y: Prognostic significance of osteopontin
expression in human prostate cancer. Int J Cancer. 118:2255–2261.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hsieh IS, Huang WH, Liou HC, Chuang WJ,
Yang RS and Fu WM: Upregulation of drug transporter expression by
osteopontin in prostate cancer cells. Mol Pharmacol. 83:968–977.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Puzone R, Paleari L, Montefiore F,
Ruggiero L, Puntoni M, Maffezzini M, Bobbio B, Marroni P, Libener R
and Betta PG: Osteopontin plasma level does not detect prostate
cancer in patients referred for diagnostic prostate biopsy. Int J
Biol Markers. 25:200–206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Tilli TM, Bellahcène A, Castronovo V and
Gimba ER: Changes in the transcriptional profile in response to
overexpression of the osteopontin-c splice isoform in ovarian
(OvCar-3) and prostate (PC-3) cancer cell lines. BMC Cancer.
14:4332014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Tilli TM, Silva EA, Matos LC, Faget DV,
Dias BF, Vasconcelos JS, Yokosaki Y and Gimba ER: Osteopontin is a
tumor autoantigen in prostate cancer patients. Oncol Lett.
2:109–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Tozawa K, Yamada Y, Kawai N, Okamura T,
Ueda K and Kohri K: Osteopontin expression in prostate cancer and
benign prostatic hyperplasia. Urol Int. 62:155–158. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hu ZD, Wei TT, Yang M, Ma N, Tang QQ, Qin
BD, Fu HT and Zhong RQ: Diagnostic value of osteopontin in ovarian
cancer: a meta-analysis and systematic review. PLoS One.
10:e01264442015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Leung DT, Lim PL, Cheung TH, Wong RR, Yim
SF, Ng MH, Tam FC, Chung TK and Wong YF: Osteopontin fragments with
intact thrombin-sensitive site circulate in cervical cancer
patients. PLoS One. 11:e01604122016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Song JY, Lee JK, Lee NW, Yeom BW, Kim SH
and Lee KW: Osteopontin expression correlates with invasiveness in
cervical cancer. Aust N Z J Obstet Gynaecol. 49:434–438. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wong JPC, Wei R, Lyu P, Tong OLH, Zhang
SD, Wen Q, Yuen HF, El-Tanani M and Kwok HF: Clinical and in vitro
analysis of Osteopontin as a prognostic indicator and unveil its
potential downstream targets in bladder cancer. Int J Biol Sci.
13:1373–1386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Xu C, Li H, Yin M, Yang T, An L and Yang
G: Osteopontin is involved in TLR4 pathway contributing to ovarian
cancer cell proliferation and metastasis. Oncotarget.
8:98394–98404. 2017.PubMed/NCBI
|
|
74
|
Xu ST, Guo C, Ding X, Fan WJ, Zhang FH, Xu
WL and Ma YC: Role of osteopontin in the regulation of human
bladder cancer proliferation and migration in T24 cells. Mol Med
Rep. 11:3701–3707. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zivny JH, Leahomschi S, Klener P Jr..Zivny
J, Haluzik M and Cibula D: Comparison of Plasma Osteopontin Levels
between patients with borderline ovarian tumours and serous ovarian
carcinoma. Folia Biol (Praha). 62:258–262. 2016.PubMed/NCBI
|
|
76
|
Jia R, Liang Y, Chen R, Liu G, Wang H,
Tang M, Zhou X, Wang H, Yang Y, Wei H, et al: Osteopontin
facilitates tumor metastasis by regulating epithelial-mesenchymal
plasticity. Cell Death Dis. 7:e25642016. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Bandopadhyay M, Bulbule A, Butti R,
Chakraborty G, Ghorpade P, Ghosh P, Gorain M, Kale S, Kumar D,
Kumar S, et al: Osteopontin as a therapeutic target for cancer. Exp
Opin Therap Targ. 18:883–895. 2014. View Article : Google Scholar
|
|
78
|
Raja R, Kale S, Thorat D, Soundararajan G,
Lohite K, Mane A, Karnik S and Kundu GC: Hypoxia-driven osteopontin
contributes to breast tumor growth through modulation of
HIF1α-mediated VEGF-dependent angiogenesis. Oncogene. 33:2053–2064.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wei R, Wong JPC and Kwok HF: Osteopontin-a
promising biomarker for cancer therapy. J Cancer. 8:2173–2183.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Todaro M, Gaggianesi M, Catalano V,
Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S,
Cocorullo G, et al: CD44v6 is a marker of constitutive and
reprogrammed cancer stem cells driving colon cancer metastasis.
Cell Stem Cell. 14:342–356. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhang N, Ying MD, Wu YP, Zhou ZH, Ye ZM,
Li H and Lin DS: Hyperoside, a flavonoid compound, inhibits
proliferation and stimulates osteogenic differentiation of human
osteosarcoma cells. PLoS One. 9:e989732014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Mortus JR, Zhang Y and Hughes DP:
Developmental pathways hijacked by osteosarcoma. Ad Exp Med Biol.
804:93–118. 2014. View Article : Google Scholar
|
|
83
|
Luo X, Chen J, Song WX, Tang N, Luo J,
Deng ZL, Sharff KA, He G, Bi Y, He BC, et al: Osteogenic BMPs
promote tumor growth of human osteosarcomas that harbor
differentiation defects. Lab Invest. 88:1264–1277. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Velupillai P, Sung CK, Tian Y, Dahl J,
Carroll J, Bronson R and Benjamin T: Polyoma virus-induced
osteosarcomas in inbred strains of mice: host determinants of
metastasis. PLoS Path. 6:e10007332010. View Article : Google Scholar
|
|
85
|
Liu SJ, Hu GF, Liu YJ, Liu SG, Gao H,
Zhang CS, Wei YY, Xue Y and Lao WD: Effect of human osteopontin on
proliferation, transmigration and expression of MMP-2 and MMP-9 in
osteosarcoma cells. Chin Med J. 117:235–240. 2004.PubMed/NCBI
|
|
86
|
Liu SJ, Zhang DQ, Sui XM, Zhang L, Cai ZW,
Sun LQ, Liu YJ, Xue Y and Hu GF: The inhibition of in vivo
tumorigenesis of osteosarcoma (OS)-732 cells by antisense human
osteopontin RNA. Cell Mol Biol Lett. 13:11–19. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Berge G, Pettersen S, Grotterød I, Bettum
IJ, Boye K and GM Ml: Osteopontin-an important downstream effector
of S100A4-mediated invasion and metastasis. Int J Cancer.
129:780–790. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Rankin EB and Giaccia AJ: The role of
hypoxia-inducible factors in tumorigenesis. Cell Death Different.
15:678–685. 2008. View Article : Google Scholar
|
|
89
|
Macheda ML, Rogers S and Best JD:
Molecular and cellular regulation of glucose transporter (GLUT)
proteins in cancer. J Cell Phy. 202:654–662. 2005. View Article : Google Scholar
|
|
90
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Hsieh IS, Yang RS and Fu WM: Osteopontin
upregulates the expression of glucose transporters in osteosarcoma
cells. PLoS One. 9:e1095502014. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Song K, Liu N, Yang Y and Qiu X:
Regulation of osteosarcoma cell invasion through osteopontin
modification by miR-4262. Tum Biol. 37:6493–6499. 2016. View Article : Google Scholar
|
|
93
|
Noda M, Yoon K, Prince CW, Butler WT and
Rodan GA: Transcriptional regulation of osteopontin production in
rat osteosarcoma cells by type beta transforming growth factor. J
Biol Chem. 263:13916–13921. 1988.PubMed/NCBI
|
|
94
|
Wong IH, Chan AT and Johnson PJ:
Quantitative analysis of circulating tumor cells in peripheral
blood of osteosarcoma patients using osteoblast-specific messenger
RNA markers: A pilot study. Clin Cancer Res. 6:2183–2188.
2000.PubMed/NCBI
|
|
95
|
Sulzbacher I, Birner P, Trieb K, Lang S
and Chott A: Expression of osteopontin and vascular endothelial
growth factor in benign and malignant bone tumors. Virch Arch.
441:345–349. 2002. View Article : Google Scholar
|
